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Abstract
Background. Hyperoxaluria is a major risk factor for
kidney stone formation. Although urinary oxalate measure-
ment is part of all basic stone risk assessment, there is no
standardized method for this measurement.
Methods. Urine samples from 24-h urine collection cover-
ing a broad range of oxalate concentrations were aliquoted
and sent, in duplicates, to six blinded international labo-
ratories for oxalate, sodium and creatinine measurement. In
a second set of experiments, ten pairs of native urine
and urine spiked with 10 mg/L of oxalate were sent for
oxalate measurement. Three laboratories used a commer-
cially available oxalate oxidase kit, two laboratories used
a high-performance liquid chromatography (HPLC)-based
method and one laboratory used both methods.
Results. Intra-laboratory reliability for oxalate measure-
ment expressed as intraclass correlation coefficient (ICC)
varied between 0.808 [95% confidence interval (CI):
0.427–0.948] and 0.998 (95% CI: 0.994–1.000), with
lower values for HPLC-based methods. Acidification of
urine samples prior to analysis led to significantly higher
oxalate concentrations. ICC for inter-laboratory reliability
varied between 0.745 (95% CI: 0.468–0.890) and 0.986
(95% CI: 0.967–0.995). Recovery of the 10 mg/L oxa-
late-spiked samples varied between 8.7 6 2.3 and 10.7 6
0.5 mg/L. Overall, HPLC-based methods showed more
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variability compared to the oxalate oxidase kit-based
methods.
Conclusions. Significant variability was noted in the quan-
tification of urinary oxalate concentration by different
laboratories, which may partially explain the differences
of hyperoxaluria prevalence reported in the literature. Our
data stress the need for a standardization of the method
of oxalate measurement.
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Introduction
The risk of passing a kidney stone during a lifetime is ~10%
and the risk of recurrence reaches 50% after the first episode.
Metabolic evaluation of recurrent stone formers is cost-
efficient and helps prevent further recurrence by guiding treat-
ment [1]. Metabolic investigation is based on 24-h urine
collections which provide the excretion rate for several iden-
tified lithogenic factors and allow the calculation of urinary
saturation with respect to stone forming salts. Since ~70% of
stones contain calcium and oxalate [2], every metabolic
workup includes measurement of calcium and oxalate concen-
trations in a 24-h urine collection, together with other key
analytes. Debate about the relative contribution of hyperoxa-
luria and hypercalciuria to the process of calcium oxalate stone
formation has been ongoing in the kidney stone community
for years [3–7]. However, a direct comparison ofoxalate meas-
urement between stone laboratories has not been performed.
Several methods have been developed to measure oxa-
late levels [8, 9], however, two methods are currently used
by most laboratories: high-performance liquid chromatog-
raphy (HPLC)-based and colorimetric oxalate oxidase
methods. HPLC-based methods are generally developed
in-house by individual centers, each using a different setup
(column, eluant, detector, retention time, etc. . .) while the
oxalate oxidase colorimetric method has been developed,
validated and largely diffused as a kit by a single vendor.
In the course of comparing stone risk profiles of stone
formers recruited from two centers, one in Europe and
one in the USA, we noted important variations in oxalate
measurements. This motivated the current study in which
we explored the intra- and inter-laboratory agreement of
oxalate assessment performed by six international labo-
ratories. We found variable agreement between laborato-
ries, stressing the importance of correct sample handling
(pre-analytic acidification) and the need for a standardiza-
tion of urinary oxalate measurement.
Materials and methods
Urine samples were obtained randomly and anonymously from kidney
stone formers presenting to the outpatient stone clinic of the University
of Texas Southwestern Medical Center (UTSW). Twenty-four-hour urine
samples were collected by carefully instructed patients and kept at 4C
without addition of any preservative or chemicals.
Experiment one
Once received by the UTSW laboratory, a regular stone risk profile was
first run on the 24-h urine collection using an HPLC-based method for
oxalate. The rest of the urine was aliquoted in 10 mL portions and frozen at
80C without addition of preservative and without acidification. Twenty
samples of 10 mL urine comprising urine samples from 10 patients in
duplicate were sent out frozen on dry ice to six international laboratories
for oxalate assessment (Lab A–F, with Laboratory D performing both
oxalate oxidase and HPLC-based method receiving two separate Labels,
D1 and D2, one for each method). The UTSW laboratory reran the frozen
samples in duplicate in a blinded fashion similar to the other laboratories.
Of note, the laboratories were blinded to sample identification and were
unaware of the fact that they received duplicates to analyze. Each labo-
ratory was instructed to thaw and acidify the samples prior to processing.
Each laboratory was also asked to determine sodium and creatinine as
control measurements. In addition, and in order to assess the role of acid-
ification on oxalate measurement, two laboratories (Laboratories D2 and
E, both using a HPLC-based method) were asked to compare oxalate
measurement from thawed urine (‘non-acidified’) and from the same urine
acidified immediately after thawing (‘acidified’).
Experiment two
Once received by the UTSW laboratory, the regular stone risk profile was
first run on the 24-h urine collection using an HPLC-based method for
oxalate. Then, urine was aliquoted by 10 mL, acidified to pH < 2 with a
solution of 12 N HCl and kept at 4C. A set of samples was spiked with 10
mg/L sodium oxalate by adding 0.1 mL of a stock solution of 1 g/L of
sodium oxalate to 9.9 mL of native urine. Ten native samples and ten
spiked samples were sent out to five international laboratories (Laborato-
ries A–E, as Laboratory F withdrew, recognizing a problem with its ox-
alate assessment method).
Oxalate levels assessment.. All participating laboratories are clinical
laboratories. Four laboratories (Laboratories A, B, C and D1) used the
same commercially available oxalate oxidase kit (Trinity Biotech, Co.
Wicklow, Ireland), following the manufacturer’s protocol, two laborato-
ries used locally setup HPLC-based method (Laboratories E and F) and
one lab used both methods (D1 and D2) (see Table 1). HPLC-based
method utilized the Dionex system, using AS22, AS4A and AS11 col-
umns (Laboratories D2, E and F, respectively). The upper limits of
linearity for the different methods were 180 mg/L for laboratories using
the oxalate oxidase kit (A, B, C, D1) and 18 mg/L, 80 mg/L and 180 mg/
L for Laboratories D2, E and F, respectively.
Statistical methods
Intra-laboratory agreement was measured by comparing results of dupli-
cate samples for oxalate, sodium and creatinine and was expressed as
intraclass correlation coefficient (ICC). Urine oxalate measured in Labo-
ratories A–E was compared in all 20 (basal and spiked) specimens using
the ICC. PASW Statistics version 17 (SPSS Inc. Chicago, IL) was used.
Results from Laboratories A–E were also compared among one another
using Bland–Altman plots [10]. Acidified and non-acidified samples were
compared by a paired Student’s t-test.
Results
Intra-laboratory comparison
We first examined the intra-laboratory variability by using
sample duplicates (Experiment 1), given that the labora-
tories were blinded regarding sample identification. All lab-
oratories were informed that the samples were not acidified
during the collection and were asked to process them accord-
ingly. Table 1 shows the ICC [and 95% confidence intervals
(CI)] for Laboratories A–F, with the exception of Laboratory
D2, from which incomplete data precluded analysis of the
ICC. Important variability was observed in the analysis of
the duplicates in three laboratories (Laboratories A and D1
using the oxalate oxidase method, and F using an HPLC-
based method). In contrast, duplicate analysis for sodium
and creatinine showed high ICC. After this initial analysis,
Laboratory F (with the lowest ICC) conducted additional
internal analyses and concluded that inconsistencies in their
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HPLC-method for oxalate determination precluded partici-
pation in Experiment 2. In summary, Experiment 1 showed
important intra-laboratory variations leading even to the
withdrawal of one laboratory from the rest of the study.
Pre-analytical acidification of the samples
All laboratories in the study routinely acidify urine samples
at the time of analysis. We next examined the role of
pre-analytical sample acidification in oxalate analysis.
Two laboratories using HPLC-based methods (D2 and E)
analyzed samples from native urine and urine acidified in
the laboratory (to pH < 2) prior to testing. As shown in
Figure 1, pre-analytical acidification of the urine samples
resulted in significantly higher oxalate concentrations in
both laboratories, possibly reflecting a better solubility of
oxalate. These data stress the importance of pre-analytical
acidification of the samples.
Inter-laboratory comparison
Taking into account, the limitations of the data set gathered
from Experiment 1, and in view of the importance of the
pre-analytical urinary acidification, we designed a second ex-
periment in which we acidified the urine shortly after it was
received in the distributing center. Acidified samples kept
at 4C were aliquoted, and duplicates were spiked with
10 mg/dL sodium oxalate and sent overnight to the participat-
ing laboratories. Figure 2 and supplementary Table 1 show
the values obtained by each individual laboratory for the 20
samples. Important variations were observed between the
laboratories, with systematic bias toward high values for
Laboratory D1 and toward low values for Laboratory A.
Analysis of the differences between the spiked samples
and the original urine was performed, and the recovery
of 10 mg/L oxalate is shown in Figure 3. Important varia-
tions of recovery were identified for all laboratories, with
coefficient of variation of 12% on average (minimum 5%,
maximum 27%) (Table 2).
To analyze in more detail the differences between the
laboratories, we established ICC for all pairs of participat-
ing laboratories. Table 3 presents the data demonstrating
ICC varying between 0.745 (95% CI: 0.468–0.890) and
0.986 (95% CI: 0.967–0.995). To visualize individual
comparisons between pairs of laboratories, we present
direct plots with the identity line drawn in dash and
Bland–Altman plots (Figure 4). Illustrated are pairs of
laboratories using the oxalate oxidase kit with high agree-
ment (Panels A and B), and laboratories using the same
method, but with lower correlation coefficient (Panels C
and D). We performed the same comparison for the two
laboratories using HPLC (Panels E and F). Finally, we
compared oxalate oxidase kit-using laboratories with
those using HPLC-derived methods. Examples of high
and low agreement (Panels G, H and I, J, respectively)
are presented.
Table 1. Analysis of the reliability within the same laboratory (analysis of the duplicates from Experiment 1)a
Laboratories
Method for oxalate
measurement Oxalate Sodium Creatinine
Lab A OO 0.875 (0.599–0.967) NA NA
Lab B OO 0.998 (0.994–1.000) 1.000 (0.999–1.000) 1.000 (0.999–1.000)
Lab C OO 0.994 (0.976–0.998) 1.000 (1.000–1.000) 1.000 (1.000–1.000)
Lab D1 OO 0.942 (0.798–0.985) 0.999 (0.997–1.000) 1.000 (0.999–1.000)
Lab D2 HPLC NA
Lab E HPLC 0.977 (0.914–0.994) 0.999 (0.996–1.000) 0.995 (0.982–0.999)
Lab F HPLC 0.808 (0.427–0.948) 1.000 (1.000–1.000) 1.000 (0.999–1.000)
aICC are presented with 95% upper and lower CI. NA stands for not available; OO, oxalate oxidase method.
Fig. 2. Individual laboratory oxalate measurements for 20 different sam-
ples from Experiment 2. Samples are arranged in order of increasing
oxalate concentration. Closed symbols represent laboratories that used
HPLC-based methods, while open symbols indicate laboratories that used
the oxalate-oxidase method.
Fig. 1. Comparison of urine oxalate measurement from paired samples
acidified and non-acidified by the laboratories prior to analysis. Acidified
samples were acidified after thawing by the receiving Laboratories (D2,
open circles, and E, closed circles) and processed for oxalate measurement
by an HPLC-based method. Data for individual sample pairs are connected
by a dashed line for Laboratory D2 and continuous line for Laboratory E.
Mean and SD is shown by the squares. P < 0.001 acidified versus non-
acidified samples, n ¼ 20 per group, with 10 samples per laboratory.
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Discussion
The goal of this study was to assess the degree of agree-
ment in urine oxalate measurements from various labora-
tories. While an excellent consistency was noted in the
measurement of urine sodium and creatinine, we observed
substantial variation in intra-laboratory (Table 1) and inter-
laboratory (Table 3) agreement in urine oxalate measure-
ment. Overall, there was some suggestion of systematic
bias for two of the laboratories (Figure 2), and HPLC-based
methods showed more variability compared to the oxalate
oxidase kit-based methods. The presence of systematic bias
between laboratories suggests that the use of a standardized
calibrator(s) could enhance between-laboratory agreement.
A number of pre-analytical factors are known to influ-
ence urine oxalate measurement [11], including the con-
version of ascorbic acid to oxalate which falsely increases
measured oxalate. This conversion occurs with longer
duration of sample storage and more rapidly at alkaline
pH and higher storage temperature. It can be minimized
by acidifying urine and/or maintaining it at temperatures
4C if stored for prolonged durations [11]. The time at
which the sample is acidified—upon collection of the urine
or right before oxalate measurement—has been shown not
to affect the measured oxalate concentration [12]. In our
experiments, non-acidified samples were frozen at 80C,
shipped on dry ice and acidified before analysis for Experi-
ment 1, while samples from Experiment 2 were acidified
shortly after the end of collection, kept at 4C, and shipped
with ice packs. In both experiments, samples were analyzed
within 10 days of collection. We therefore feel that pre-
analytical handling is unlikely to have contributed to
the variance in urine oxalate measurement between
laboratories.
We did note a significant difference in HPLC-measured
oxalate concentrations when samples were run acidified
versus non-acidified (Figure 1). This might reflect a better
solubility of oxalate in acidified urine or a direct effect of
the pH on the chromatography.
Urine oxalate measurement is routinely performed in the
evaluation of patients with nephrolithiasis. Initially intro-
duced three decades ago [13], the enzymatic method for
determining oxalate concentration in urine using oxalate
oxidase is now available through a commercially available
kit (Trinity Biotech). This kit was used by four laboratories
participating in our studies, Laboratories A, B, C and D1.
Among themselves, Laboratories B, C and D1 showed
excellent intra- and inter-laboratory reliability (ICC for
analysis of duplicates 0.942–0.998 and for inter-laboratory
comparison 0.932–0.979—Tables 1 and 3 and Figure 4A
and B). On the other hand, Laboratory A, using the same
kit, displayed lower intra-laboratory reliability (ICC:
0.875) and less agreement with the other laboratories, with
a tendency for returning lower values (Figures 2 and 4C
and D). This could reflect handling problems of the samples
or any aspect of assay performance. HPLC was adapted for
the measurement of urine oxalate a few years after the
oxalate oxidase method [14–16] and is less expensive once
Table 2. Results of recovery of 10 mg/L of oxalate from Experiment 2 shown as mean, percentage of recovery and percentage of coefficient of variation
for each laboratory
Laboratory A B C D1 D2 E
Mean (mg/L) 9.68 10.53 10.74 10.67 8.68 10.12
SD (mg/L) 1.38 0.71 0.53 0.93 2.34 0.93
Recovery (%) 96.8 105.3 107.4 106.7 86.8 101.2
CV (%) 14.21 6.71 4.89 8.76 26.98 9.17
Table 3. ICC for urine oxalate measured in six different laboratories by two different methods (oxalate oxidase: Laboratories A, B, C, D1, clear
background; HPLC-based: Laboratories D2 and E, gray background)
A B C D1 D2 E
A 1
B 0.838 (0.640–0.932) 1
C 0.925 (0.823–0.969) 0.977 (0.943–0.991) 1
D1 0.745 (0.468–0.890) 0.979 (0.949–0.992) 0.932 (0.840–0.972) 1
D2 0.842 (0.649–0.934) 0.925 (0.824–0.970) 0.931 (0.836–0.972) 0.893 (0.753–0.956) 1
E 0.865 (0.696–0.944) 0.986 (0.967–0.995) 0.984 (0.961–0.994) 0.966 (0.917–0.986) 0.927 (0.827–0.970) 1
Fig. 3. Recovery of 10 mg/L spike in oxalate in different laboratories
participating in Experiment 2. Closed symbols represent laboratories that
used HPLC-based methods, while open symbols indicate laboratories that
used the oxalate-oxidase method.
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Fig. 4. (A–J) Between laboratory agreement from Experiment 2. (A, C, E, G, I) Direct comparison between indicated pairs of laboratories is shown with
dashed identity line and trend line in solid. (B, D, F, H, J) Bland–Altman plots for the same pairs of laboratories. Solid line represents the mean bias and
the dashed lines indicate upper and lower limits of agreement. Panels A and B show pairs of highly correlated laboratories using the oxalate oxidase kit,
while Panels C and D compare laboratories with lower correlation coefficients using the same method. Panels E and F show comparison between the two
laboratories using HPLC-based methods. Panels G, H and I, J show pairs in which one laboratory uses the oxalate oxidase method, with the other using an
HPLC-derived method, and presenting high (Panels G and H) or weak agreement (Panels I and J).
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the method is established in the laboratory. Laboratories
utilize different columns, solvents, detectors and retention
times for oxalate detection. Although laboratories periodi-
cally perform internal validation studies, external valida-
tion may not be performed on a regular basis. In our study,
Laboratory F utilizing HPLC displayed very low intra-
laboratory reliability and eventually identified a problem
with its method to isolate oxalate (it was measuring an
additional compound besides oxalate, hidden in the same
peak) and withdrew from the rest of the study. Laboratory
D2 utilizing HPLC displayed lower inter-laboratory ICCs
(0.842–0.931), while Laboratory E, also utilizing HPLC,
displayed better agreement with Laboratories B, C and D1
which utilizes the oxalate oxidase kit (ICC: 0.966–0.986).
Our findings suggest that direct comparison of urinary
oxalate concentrations measured by different laboratories
is not always possible. This is clinically important as dis-
crepancies in the prevalence of hyperoxaluria between
various stone centers could be due to differences in oxa-
late measurement rather than to dietary or genetic factors.
Furthermore, a number of investigators have debated the
relative roles of urinary calcium and oxalate in the for-
mation of calcium oxalate stones [3–7]. Some of the argu-
ments provided are based on results of metabolic studies,
in which urinary oxalate was measured by various techni-
ques. We propose that variations of the measurement of
oxalate in the urine may have led to overestimation or
underestimation of the real prevalence of hyperoxaluria
in the population of stone formers.
Limitations of this study include the small sample size
and the fact that not all methodologies available for oxalate
measurement were evaluated. However, samples were an-
alyzed by the two most commonly used techniques. Fur-
thermore, oxalate concentrations evaluated were within the
reference range, but lower than what one may see in pa-
tients with primary hyperoxaluria.
In this study assessing the degree of agreement in
urine oxalate measurements from various laboratories,
significant variability was noted between laboratories.
Our findings stress the need for a standardization of
the method of measurement in order to allow accurate
comparison of urinary oxalate values between laborato-
ries. Use of an international calibrator might help in
improving some systematic bias noted for some
laboratories.
Supplementary data
Supplementary Table 1 is available online at http://ndt.
oxfordjournals.org.
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